[Semax in prevention of disease progress and development of exacerbations in patients with cerebrovascular insufficiency].
Gusev. E I EI; Skvortsova. V I VI; Chukanova. E I EI
Key Findings
- Semax led to significant clinical improvement in patients with cerebrovascular insufficiency.
- The treatment stabilized disease progression and lowered the risk of stroke and transient ischemic attacks.
- Side effects were rare and mild, and the peptide was well tolerated across age groups.
Practical Outcomes
- For biohackers focused on brain health, Semax appears to be a safe, neuroprotective agent that may help maintain cerebrovascular function and reduce stroke risk. While the study involved patients with existing vascular issues, the safety profile suggests it could be explored as a preventative supplement in at‑risk individuals, pending further research on dosing for healthy users.
Summary
In a study of 187 people with reduced blood flow to the brain, the peptide Semax was given as a treatment. Patients who took Semax showed clear improvements in neurological symptoms, a slower progression of their condition, and a lower chance of having a stroke or mini‑stroke. The drug was well tolerated, with only a few mild side effects, even in older participants.
Abstract
One hundred and eighty-seven patients with different stages of cerebrovascular insufficiency (CI) have been examined. A diagnosis of CI was based on the results of neurological and neuropsychological study, ultrasonic dopplerography, rheo- and encephalography, electrocardiography, brain MRI and eyegrounds examination. Neurological scales were used for neurological status assessment and further data processing. The study aimed at evaluation of tolerability and clinical efficacy of the medication and complications in CI course. Semax treatment resulted in significant clinical improvement, stabilization of the disease progress and reduced a risk of stroke and transitory ischemic attacks in the disease course. The drug is featured by minor percent of side-effects and is well tolerated by patients, including those of older age groups.
Study Information
pubmed
2005